Nuwellis Inc

Nuwellis has appointed Dale Brady as lead R&D engineer. Brady brings more than 25 years of medtech experience, multiple U.S. patents and leadership roles at Peytant Solutions, Endogenex and Osprey Medical. He will lead internal product development programs and bolster the research and development team. » More on de.investing.com

Nuwellis sold 1,310,890 common shares at $2.59 each in a registered direct placement, securing total proceeds of about $3.4 million, including roughly $3.1 million from the exercise of previously issued warrants. At the same time, Nuwellis will issue warrants to purchase up to 1,310,890 shares at an exercise price of $2.59; these are immediately exercisable and have a five‑year term. The closing of the offerings is expected on August 3, 2026, subject to customary conditions; Ladenburg Thalmann & Co. is acting as exclusive placement agent. » More on de.investing.com

Nuwellis completed a public offering that generated gross proceeds of about $6.0 million for the medical technology company. 1,903,338 common shares and pre-funded warrants to purchase 18,096,662 common shares were sold; in addition, Series C warrants (up to 60 million shares) and Series D warrants (up to 20 million shares) were issued. The public offering price was $0.30 per share; the pre-funded warrants were offered at $0.2999 and are immediately exercisable at $0.0001. The stock last traded at $0.14, market capitalization is about $0.38 million, and the company shows a negative free cash flow of $11.51 million according to the data. Ladenburg Thalmann acted as sole book‑running manager; the securities were offered under an S‑1 registration that became effective on June 4, 2026. » More on de.investing.com